Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Are Randomized Controlled Trials the (G)old Standard? From Clinical Intelligence to Prescriptive Analytics
46
Zitationen
4
Autoren
2016
Jahr
Abstract
Despite the accelerating pace of scientific discovery, the current clinical research enterprise does not sufficiently address pressing clinical questions. Given the constraints on clinical trials, for a majority of clinical questions, the only relevant data available to aid in decision making are based on observation and experience. Our purpose here is 3-fold. First, we describe the classic context of medical research guided by Poppers’ scientific epistemology of “falsificationism.” Second, we discuss challenges and shortcomings of randomized controlled trials and present the potential of observational studies based on big data. Third, we cover several obstacles related to the use of observational (retrospective) data in clinical studies. We conclude that randomized controlled trials are not at risk for extinction, but innovations in statistics, machine learning, and big data analytics may generate a completely new ecosystem for exploration and validation.
Ähnliche Arbeiten
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
2021 · 91.427 Zit.
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
2009 · 83.126 Zit.
The Measurement of Observer Agreement for Categorical Data
1977 · 78.200 Zit.
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
2009 · 63.681 Zit.
Measuring inconsistency in meta-analyses
2003 · 62.337 Zit.